
Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) – HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.71) per share for the year, down from their prior forecast of ($2.70). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.78) EPS.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01.
Other equities analysts have also recently issued reports about the stock. William Blair upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Benchmark reissued a “buy” rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. Finally, Needham & Company LLC set a $25.00 target price on shares of Kyverna Therapeutics in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $29.00.
Check Out Our Latest Report on Kyverna Therapeutics
Kyverna Therapeutics Price Performance
KYTX opened at $4.76 on Tuesday. The company’s 50 day moving average is $6.15 and its 200-day moving average is $7.86. Kyverna Therapeutics has a 1-year low of $4.49 and a 1-year high of $13.67. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06.
Institutional Trading of Kyverna Therapeutics
Hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in shares of Kyverna Therapeutics during the third quarter worth about $488,000. Goldman Sachs Group Inc. raised its holdings in Kyverna Therapeutics by 64.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 551,899 shares of the company’s stock valued at $3,753,000 after buying an additional 216,669 shares during the last quarter. Marshall Wace LLP bought a new position in Kyverna Therapeutics in the 3rd quarter valued at approximately $498,000. Empowered Funds LLC acquired a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $127,000. Finally, Kovack Advisors Inc. acquired a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $65,000. 18.08% of the stock is owned by institutional investors and hedge funds.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.
See Also
- Five stocks we like better than Kyverna Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
